Point Biopharma’s radiopharmaceutical prostate cancer therapy, PNT2002, reached its main goal in a clinical trial, yet questions were raised about its effectiveness against a similar Novartis drug. The Point therapy showed a 29% reduction in the risk of radiographic progression or death compared to control drugs, but was less effective than expected, potentially impacting the commercial viability of PNT2002. Point and partner Lantheus plan to report further data next year.
Mayo Clinic-Backed Corvus Launches to Fix the Surgical Referrals Process
Corvus, a Chicago-based startup aiming to simplify the surgical referrals process, announced its launch. The company’s AI platform helps healthcare teams manage inbound surgical referrals
